当前位置：阿仪网 > 上海雅吉生物科技有限公司>公司新闻>小鼠胚胎成纤维细胞3T3-J2（文献引用）
企业档案
会员类型：旗舰版
已获得阿仪网信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网旗舰版会员：9年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
参观次数：6348451
手机网站：http://wap.app17.com/c137908/
旗舰版网址：http://www.yajiml.com
公司新闻
小鼠胚胎成纤维细胞3T3-J2（文献引用）
点击次数：179发布时间：2026/9/9 9:18:33
文章标题：Separation of Human P63+ Lung Progenitor Cells from Growth-Arrested Feeders Using Multidimensional Double Spiral Inertial Microfluidics for Efficient Bioprocessing
作者列表：Weilu Huang, Xuxia Zhu, Lanlan Zhu, Yang Qiao, Zheng Zhang, Kangkang Ren, Shaowen Li, Xinping Xu, Lu Yin
影响因子：7.3
期刊：ANALYTICAL CHEMISTRY
发表时间：2026-5-13
DOI:10.1021/acs.analchem.5c08169
文献主题：Abstract
Recent clinical trials have highlighted the potential of P63+ lung progenitor cell （LPC） transplantation for lung repair ａnd regeneration. Currently, ex vivo P63+ LPC expansion depends on coculture with growth-arrested fibroblast feeder cells （GAFs）, necessitating repeated purification during passaging. While differential enzymatic digestion （DED） ａnd fluorescence- or magnetic-activated cell sorting techniques （FACS/MACS） offer partial solutions, a scalable, efficient, ａnd consistent separation technique remains unmet, particularly for cell therapy manufacturing. Here, we present a multidimensional double spiral （MDDS） inertial microfluidic device designed for high-throughput label-free enrichment of P63+ LPCs. The MDDS device achieves cell size-based separation of P63+ LPCs ａnd growth-arrested feeder cells, processing at a rate of 106 to 107 cells per minute. MDDS-sorted P63+ LPC purity correlates with the LPC-to-GAF ratio in culture. With an initial ratio >1:1, it yields P63+ LPC purity exceeding 80%. Moreover, the device consistently recovers >80% of P63+ LPCs, with the unrecovered fraction enriched in senescent cells exhibiting compromised clonogenicity ａnd differentiation capacity. In direct benchmarking against DED ａnd FACS, the MDDS device delivered a balanced performance in terms of purity ａnd recovery, while offering advantages in throughput, consistency, ａnd scalability. We propose that this technology could enable more consistent ａnd efficient enrichment of feeder-cultured P63+ LPCs, thereby supporting more robust clinical manufacturing processes.
